Lentiviral Vectors Market

Lentiviral Vectors Market, By Product Type (1st-generation, 2nd-generation, and 3rd-generation), By Indication (HIV, β-thalassemia, X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy, and Wiskott-Aldrich Syndrome), By End User (Hospitals, Clinics, and Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Lentiviral vectors are potential gene transfer vehicles used in both research and gene therapy applications. Lentiviral vectors are effective means of transferring genes because they can stably express a desired gene in non-diverging and diving cells. Lentiviral vectors are used for the treatment of various rare genetic disorders such as β-thalassemia, X-linked Adrenoleukodystrophy, X-linked severe combined immunodeficiency (SCID-X1), and Metachromatic Leukodystrophy. Lentiviral vectors derived from the human immunodeficiency virus (HIV-1) have become major tools for gene delivery in mammalian cells. The advantageous feature of lentivirus vectors is the ability to mediate potent transduction and stable expression in dividing and non-dividing cells both in vitro and in vivo. Lentiviruses have the unique ability among retroviruses of being able to infect non-cycling cells. Vectors derived from lentiviruses have provided a huge advancement in technology and seemingly offer the means to achieve significant levels of gene transfer in vivo. Lentiviral vectors (LV) are widely used in gene therapy and genome editing. Its manufacturing is progressing towards the use of stable producer cell lines, whether inducible or constitutive. Both stable cell lines are genetically engineered to suppress LV cytotoxicity, either temporarily or permanently. Moreover, various market players are focusing on increasing their research & development activities for gene therapies including lentiviral vectors, in order to enhance their product portfolio, which is expected to drive growth of the global lentiviral vectors market over the forecast period.

Market Dynamics

Market players are focusing on adopting various inorganic growth strategies, such as agreements, acquisitions, partnerships, and collaborations, in order to strengthen its market presence, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, on April 07, 2020, SIRION Biotech GmbH, a biotechnology company specializes in functional gene analysis, announced that it entered into an agreement with Beam Therapeutics, a biotechnology company, which is focusing on the use of CRISPR technology for the development of advanced genetic medicines. Under this agreement, SIRION Biotech GmbH provided the non-exclusive access of its proprietary lentiviral transduction enhancer LentiBOOST, to Beam Therapeutics for clinical development and commercialization of CAR-T programs.

Key features of the study:

• This report provides in-depth analysis of the global lentiviral vectors market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global lentiviral vectors market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Thermo Fisher Scientific Inc., Sirion-Biotech GmbH (Revvity), Vector Biolabs, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological, Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, bluebird bio, Inc., Cellomics Technology, LLC., Virica Biotech, Oxford Biomedica, and ANDELYN BIOSCIENCES.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global lentiviral vectors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lentiviral vectors market

Detailed Segmentation:

• Global Lentiviral Vectors Market, By Product Type:
• 1st-generation
• 2nd-generation
• 3rd-generation
• Global Lentiviral Vectors Market, By Indication:
• HIV
• β-thalassemia
• X-linked Adrenoleukodystrophy
• Metachromatic Leukodystrophy
• Wiskott-Aldrich Syndrome
• Global Lentiviral Vectors Market, By End User:
• Hospitals
• Clinics
• Research Institutes
• Global Lentiviral Vectors Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Thermo Fisher Scientific Inc.
• Sirion-Biotech GmbH (Revvity)
• Vector Biolabs
• OriGene Technologies, Inc.
• SignaGen Laboratories
• Sino Biological, Inc.
• Takara Bio Inc.
• Cell Biolabs, Inc.
• GenTarget Inc.
• GENEMEDI
• bluebird bio, Inc.
• Cellomics Technology, LLC.
• Virica Biotech
• Oxford Biomedica
• ANDELYN BIOSCIENCES